RED BANK, NJ–(Marketwire -01/13/12)- American CryoStem Corporation (OTC.BB: CRYO.OB – News) announces the branding of “ACS Laboratory Services.”
As of January 2012 we have branded our adipose tissue processing facility “ACS Laboratory Services.” This new branding reflects the Company’s increasing commercialization of products and services developed for its proprietary clinical tissue processing methodologies. We have begun offering the first of these products for sale and license which are based on our granted patent (Cell Culture Media, Kits and Methods of Use,” (US 7,898,205 B2)). The product line is the first patented culture, growth and differentiation media specifically designed for use with adipose derived stem cells (ADSC) and is ideally suited for the conversion of new ADSC therapies from research to clinical application. The media is available in both research and clinical grade, in 100ml to 1 liter ready to use quantities. The product line includes undifferentiated growth media, and adipogenic, chondrogenic, and osteogenic differentiation media. The clinical grade media are free from animal (xenomorphic) serum and additives which make them ideally suited for the expansion and differentiation of ADSCs intended for clinical use.
We made our first commercial sale of our media products this month and have begun marketing to increase industry recognition and sales. We currently have a new website www.acslaboratories.com under construction to support this new product offering and all future products and services commercialized by ACS Laboratories.
David Moscatello, Chief Scientist, stated, “I am very excited to have begun offering these products to my colleagues working with ADSCs and believe that these products will assist them in the acceleration of their treatment development. We have additional products and services in various stages of development based on our patented technologies and core adipose tissue processing platform that will be unveiled during the coming year.”
John S. Arnone, CEO, stated, “We are very enthusiastic to be able to announce the commercialization and initial sales revenue from products developed from our recently issued patent. During 2011 we have been the beneficiary of increased dialogue and involvement from both doctors and researchers regarding our services and products under development. Our overall philosophy concerning the services offered by ACS Laboratories is to offer clinical grade products that are free from animal materials that can relieve some of the costs and the significant and increasing regulatory burdens for developers of cellular technologies. These burdens are evidenced in the U.S. Department of Health and Human Services and the FDA’s regulations and guidance for manufacturers and developers in relation to the inclusion of xenomorphic (animal) material in the manufacturing and marketing of new and existing cellular products.”
About American CryoStem: The Company markets a core clinical processing platform for Adipose (fat) Derived Adult Stem Cells. The Company’s services provide for the collection, processing, and cryopreservation (long term storage) of adult stem cells, allowing healthy individuals to privately preserve their stem cells for future use in personalized and regenerative medicine at an affordable price. Adult Stem Cells treatments are currently being utilized to potentially heal one’s own body of diseases and chronic conditions. The Company’s proprietary platform provides streamlined and affordable processing and cryopreservation of Adipose Derived Stem Cells (ADSCs) and Adipose Tissue (AT) for autologous use.
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain of the statements contained herein, which are not historical facts, are forward-looking statements with respect to events, the occurrence of which involve risks and uncertainties.
These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the Company is detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission.